Zobrazeno 1 - 10
of 1 133
pro vyhledávání: '"eslicarbazepine"'
Autor:
Nastaran Afsordeh, Safura Pournajaf, Hadi Bayat, Fatemeh Mohajerani, Amir Shojaei, Javad Mirnajafi-Zadeh, Mohammad Hossein Pourgholami
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Glioblastoma multiforme (GBM) is the most malignant brain tumor, with a poor prognosis and life expectancy of 14–16 months after diagnosis. The standard treatment for GBM consists of surgery, radiotherapy, and chemotherapy with
Externí odkaz:
https://doaj.org/article/64236aaaafa7439092e387c8c2d2419f
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe approval of eslicarbazepine acetate (ESL) by the Food and Drug Administration (FDA) in 2013 marked an advancement in the treatment of adult patients with partial-onset seizures. However, there still remains a paucity of real-world studi
Externí odkaz:
https://doaj.org/article/2f7dcfba14e842dfa08a260a6cc5f1f0
Publikováno v:
Epilepsia Open, Vol 9, Iss 1, Pp 404-408 (2024)
Abstract Hyponatremia is a typical side effect of antiseizure drugs from the dibenzazepine family. The study investigated the prevalence of hyponatremia in patients with epilepsy who were treated with eslicarbazepine. We aimed to determine the preval
Externí odkaz:
https://doaj.org/article/3a9861b86b894641b425c303883c10e7
Autor:
Rumyana Kuzmanova, I. Vaneva
Publikováno v:
Българска неврология, Vol 25, Iss 1 (2024)
Епилепсията е едно от най-честите неврологични заболявания и засяга приблизително 70 милиона души по света. Лечението на епилепсията е п
Externí odkaz:
https://doaj.org/article/0a517c6f1b3348ed956ed3c8a78bba6f
Publikováno v:
Эпилепсия и пароксизмальные состояния, Vol 15, Iss 2, Pp 160-170 (2023)
The review considers pharmacological characteristics of new antiepileptic drugs (AEDs) of the third generation such as eslicarbazepine, lacosamide, retigabine, perampanel, everolimus, brivaracetam, zonisamide. The data on the mechanisms of action, ph
Externí odkaz:
https://doaj.org/article/8037a813e7434170ab3a33083f63cfd9
Autor:
Jaime Gonçalves-Sánchez, Thomas Ramírez-Santos, Dolores E. López, Jesús M. Gonçalves-Estella, Consuelo Sancho
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 1121 (2024)
Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug indicated as monotherapy for adults with newly diagnosed epilepsy and as adjunctive therapy for the treatment of partial seizures. Our aim was to assess the effectiveness and safe
Externí odkaz:
https://doaj.org/article/d6ab939b11914d378f1ed301471ab34e
Autor:
Hamada Altalib, Todd Grinnell, David Cantu, Fábio Ikedo, Mariana Vieira, Yi Zhang, David Blum
Publikováno v:
Epilepsia Open, Vol 7, Iss 4, Pp 616-632 (2022)
Abstract Objective Eslicarbazepine acetate (ESL) is a once‐daily (QD), oral anti‐seizure medication for the treatment of focal (partial‐onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment‐emergent adve
Externí odkaz:
https://doaj.org/article/d3026b02cce5409bb9490b2ea2f5cf9d
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 16, Pp 4091-4099 (2022)
Ping Liu,1,2 Jing An,2 Huizhen Wu1,2 1Graduate School of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei General Hospital, Shijiazhuang, People’s Republi
Externí odkaz:
https://doaj.org/article/be26f0ed74e743b29484ea252753d8c2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.